Myanmar

The primary regulatory authority for health products in Myanmar is the Food and Drug Administration (FDA) under the Ministry of Health. The principal governing legislation is the Food and Drug Law (2018), which consolidated and modernized earlier frameworks and established a unified licensing and registration system for pharmaceuticals, medical devices, diagnostics, and related health products. All health products intended for sale or distribution in Myanmar must undergo product registration with the FDA before market entry. The registration process involves submission of a dossier, laboratory testing, factory inspection (for manufacturers), and review by relevant technical committees. The FDA issues registration certificates that are typically valid for three to five years and require renewal upon expiry.

Myanmar generally follows the ASEAN Common Technical Dossier (ACTD) format for pharmaceutical submissions, aligning with regional harmonization efforts under the ASEAN Pharmaceutical Product Working Group (PPWG). For medical devices and diagnostics, the FDA has been developing a risk-based classification framework broadly consistent with ASEAN Medical Device Directive (AMDD) principles, though implementation remains in progress. A local registered agent or authorized representative based in Myanmar is required for all foreign manufacturers seeking product registration. Post-2021, regulatory operations have experienced significant disruptions due to the political transition, leading to processing delays and reduced institutional capacity. Despite these challenges, the FDA has continued to accept and process submissions, and some procedural digitization efforts initiated in earlier years remain partially in use. Applicants are advised to engage local regulatory consultants familiar with current administrative conditions.

Public procurement of health products in Myanmar is primarily coordinated through the Ministry of Health, with the Central Medical Stores (CMS) playing a key operational role in warehousing and distribution of medicines and medical supplies to public health facilities. National-level procurement is governed by the Union Government's procurement rules and overseen by the Ministry of Planning and Finance, with the Ministry of Health identifying requirements and managing technical specifications. Tendering is conducted through open and selective competitive processes, and suppliers must typically hold valid FDA registration for the products they supply. The public health system is organized across union, state, and regional levels, with health departments at state and region level managing some procurement independently, though strategic commodities are largely centrally procured. Budget constraints and ongoing political instability have significantly affected the volume and reliability of public procurement since 2021.

Myanmar has historically relied heavily on international donor and multilateral funding to supplement public health procurement, with organizations such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, UNICEF, the World Health Organization (WHO), USAID, and Gavi, the Vaccine Alliance playing substantial roles in financing and supplying essential medicines, vaccines, diagnostics, and health commodities. These donor-funded channels often procure through international competitive tendering using UN or donor procurement standards, and products supplied through these mechanisms may benefit from expedited or parallel regulatory pathways. The private sector is a significant channel for health product distribution, served through licensed importers, wholesalers, and retail pharmacies concentrated in major urban centers such as Yangon and Mandalay. Local manufacturing capacity remains limited, and while there is no formal statutory local manufacturing preference policy, the government has expressed strategic interest in developing domestic pharmaceutical production capacity as part of longer-term health system strengthening objectives.